The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor-negative tumors in MMTV-erbB2 mice

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6224-6231

  Li, Yuxin ^a   Zhang, Yun ^a   Hill, Jamal ^a   Shen, Qiang ^a   Kim, Hee Tae ^a   Xu, Xiaochun ^b   Hilsenbeck, Susan G ^a   Bissonnette, Reid P ^c   Lamph, William W ^c   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; BEXAROTENE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; RALOXIFENE; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER INVASION; CANCER PREVENTION; CARCINOMA IN SITU; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; LONG TERM CARE; LOW DRUG DOSE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRECANCER; PRIORITY JOURNAL;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL LINE, TUMOR; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NICOTINIC ACIDS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TETRAHYDRONAPHTHALENES; TIME FACTORS; TRANSGENES;

EID: 35949000084     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2681     Document Type: Article

References (26)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766-92.
3. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
5. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
6. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005;23:1636-43.
7. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
8. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
9. Wu K, Kim HT, Rodriquez JL, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 2002;11:467-74.
10. Wu K, Kim HT, Rodriquez JL, et al. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 Tantigen-transgenic mice. Clin Cancer Res 2000;6:3696-704.
11. Wu K, Zhang Y, Xu XC, et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-80.
12. Yang LM, Tin UC, Wu K, Brown P. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia 1999;4:377-88.
13. Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol 2004;51:25-32.
14. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790-5.
15. Rendi MH, Suh N, Lamph WW, et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor β-dependent apoptosis in breast cancer. Cancer Res 2004;64:3566-71.
16. Suh N, Lamph WW, Glasebrook AL, et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 2002;8:3270-5.
17. Love JD, Gooch JT, Benko S, et al. The structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12. J Biol Chem 2002;277:11385-91.
18. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu proto-oncogene in themammary epitheliumof transgenicmice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
19. Medina D, Kittrell F. Establishment of mouse mammary cell lines. In: Ip, Asch, editors. Methods in mammary gland biology and breast cancer research. New York: Kluwer Academic/Plenum Publishers; 2000. p.137-44.
20. 1 cell cycle blockade. Breast Cancer Res Treat 2006;96:147-57.
21. Hutchinson JN, Muller WJ. Transgenic mouse models of human breast cancer. Oncogene 2000;19:6130-7.
22. Campiglio M, Normanno N, Menard S. Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2004;96:715; author reply 715-6.
23. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24.
24. Liby K, Rendi M, Suh N, et al. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res 2006;12:5902-9.
25. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006;9:13-22.
26. Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006;9:23-32.